ProBioGen Achieves Merus Milestone

Betta Pharmaceuticals to develop and commercialize in China Merus’ MCLA-129

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a service and technology provider for complex antibodies and glycoproteins, achieved an undisclosed milestone payment from Merus N.V. based on Merus’ grant of an exclusive license to Betta Pharmaceuticals to develop and commercialize in China Merus’ MCLA-129, Biclonics bispecific antibody for the potential treatment of cancer. The drug uses ProBioGen’s GlymaxX antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology for greater cell-killing potential. Merus’ use...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters